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Abstract 
Brian R. Davies: Identification of Novel Binding Sites of the SWI/SNF Complex 
Member SNF5 in Malignant Rhabdoid Tumors 
(Under the Direction of Dr. Bernard Weissman) 
 
Malignant Rhabdoid Tumors (MRTs) show a loss of SNF5, a core subunit of the 
SWI/SNF chromatin remodeling complex.  These cancers are genetically stable, 
but epigenetically unstable.  We hypothesize that SNF5 loss fuels MRT 
development through aberrant gene expression by disruption of SWI/SNF 
remodeling.  Introduction of SNF5 into MRTs activates the Rb-E2F pathway, 
resulting in G1 arrest.  However, this pathway cannot completely account for the 
arrest.  We identified two novel SNF5 targets that may contribute to arrest by 
PCR Array, Cyclin G2 and HERC5.  Both show an increase in mRNA expression 
and SNF5 binding to their promoters by ChIP.  Use of 4x44k expression arrays 
revealed that GDF15 might be a third novel target.  Expression increases by 
mRNA and protein, but ChIP is needed for validation.  These genes may be 
regulated by SNF5 and contribute to arrest after chromatin remodeling increases 
expression, possibly providing further insight into MRT development. 
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Chapter 1: Introduction 
 
SWI/SNF Complex 
 
The SWI/SNF chromatin-remodeling complex is a member of a family of 
ATP dependent chromatin remodeling complexes. This complex is evolutionarily 
conserved from yeast to humans and plays a role in a large variety of cellular 
processes (1).  The complex was originally characterized in yeast, and its name 
is based on the phenotypes observed when its components were deleted.  
Mutants that could not switch mating type (SWI) or that could not ferment 
sucrose (Sucrose Non-Fermenting, SNF) were linked to defects in this complex.  
In mammalian cells, the complex contains two mutually exclusive ATPase 
proteins, BRM (Brahma) or BRG1 (Brahma-related gene 1).  These ATPases use 
the energy derived from ATP hydrolysis to break and reform nucleosome-DNA 
interactions.  This process can lead to nucleosome sliding or eviction from the 
promoter regions of genes that are regulated by the SWI/SNF complex (1).   
The full complement of genes that are regulated by the SWI/SNF complex 
are not known, however high throughput efforts are underway to address this 
question (2).  Alteration to nucleosome positioning or occupancy through 
remodeling processes can affect transcription factor binding.  Thus, the complex 
can fundamentally alter the level of transcription of genes that are molecular 
targets of the complex.  The complex itself usually contains 9-12 total subunits, 
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including four core subunits and various accessory subunits that can vary based 
on cell type or differentiation state.  The core complex is composed of one 
ATPase, BAF155, BAF170, and SNF5 (SMARCB1, INI1, BAF47) (3).  This is 
based on in vitro studies that have found that these four subunits can generate 
chromatin remodeling activity that is comparable to that of the entire complex (3).  
However, in vivo studies have found that the complex can still form and has 
some level of activity without the presence of SNF5 (4).  
 A wide variety of data has linked the SWI/SNF complex to cancer.  This 
association can be at the level of the complex itself or with individual subunits 
within the complex.  Presence of the functional complex is required for p53 
transactivation of p53 regulated genes (5).  The complex itself physically 
associates with p53, and is thought to help regulate its gene transcription and 
tumor suppressor activities (5).  BRG1 loss has been observed in approximately 
30% of non small cell lung cancers, implicating this protein as a tumor 
suppressor gene (6).  SNF5 loss has been observed in several cancer types, 
including malignant rhabdoid tumors (MRTs), choroid plexus carcinomas, and 
familial schwannamatosis (7).  The presence of SNF5 is required for 
embryogenesis, as homozygous loss of SNF5 in mouse models is embryonic 
lethal, with conditional inactivation in mouse models leading to aggressive tumor 
formation (1).  Taken together, these data indicate that SNF5 functions as a 
tumor suppressor gene.  The role of BAF170 and the need for its presence in the 
core complex is unclear at this point (7).  BAF155 is believed to play a role in the 
assembly and maintenance of stability of the complex (7). Interactions of the 
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complex with other tumor suppressor genes, such as c-MYC and MLL, have also 
been noted (1).  Through microarray analysis SWI/SNF has been found to be 
involved in repression of gene expression more so than activation (1).  Therefore, 
aberrant overexpression of critical target genes is thought to be a major 
contributing factor to cancer development when the complex is not functioning 
properly. 
 ATP-dependent chromatin remodeling is a type of epigenetic regulation.  
Epigenetic changes are those heritable changes to gene expression that do not 
alter the DNA sequence (8).  These changes can occur to either the DNA itself, 
such as methylation, or to histones, such as histone methylation.  These two 
forms of epigenetic changes are the primary mechanisms by which epigenetic 
alterations are thought to contribute to tumorigenesis (8).  Other types of 
epigenetic regulation include non-coding RNAs and histone substitution.  Other 
types of chromatin remodelers have different molecular targets and different 
activities than the SWI/SNF complex.  The interplay of all forms of epigenetic 
changes with the SWI/SNF complex creates a complex and dynamic system that 
can affect gene expression.  The interplay between the polycomb repressive 
complex and SWI/SNF demonstrates this complexity.  For example, SWI/SNF 
can mediate polycomb eviction from the p16INK4A promoter region, resulting in 
increased protein expression (9).   
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SNF5 and Malignant Rhabdoid Tumors 
  
Malignant Rhabdoid Tumors (MRTs) are a rare and deadly form of 
pediatric cancer that typically develops at a young age.  The average age of 
development is 15 months, though diagnosis can occur as early as birth (10).   
Pediatric neoplasms represent an exceptionally challenging subset of cancers to 
effectively treat.  Physicians must weigh the benefits and risks of exposing young 
children to aggressive chemotherapeutic and radiation regimens, as these 
treatments can result in extreme toxicities leading to cessation of treatment and 
developmental defects later in life (11). The standard procedure involves tumor 
resection when possible, followed by radiation and finally chemotherapy (11).  
The aggressive nature of these tumors is evident during treatment, as patients 
often die before chemotherapy can be initiated or early in treatment (11).  
Overall, the four year survival rate is only 8.8% with no effective radiation or 
chemotherapeutic treatment currently available (10).     
MRTs can arise in almost any soft tissue of the body, including the brain 
(Atypical Teratoid/Rhabdoid Tumors or AT/RTs).  These tumors typically contain 
a mixture of cell types, including classic rhabdoid cells (12).  Rhabdoid cells 
display a large nucleus, nucleolus, and eosinophilic inclusions in the cytoplasm 
(12).  Due to a lack of consistent cell types present within the tumor mass, 
negative immunohistochemical staining for SNF5 has become the defining 
characteristic for diagnosis of a MRT or AT/RT (12).  The cell type or tissue of 
origin is currently unknown.  Comparison of kidney derived MRT lines with other 
kidney tumor types has revealed a decrease in expression of neural 
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differentiation related genes, which is interesting due to the fact that MRTs can 
be found in brain and neural tissues (13).  Such observations have lead to the 
idea that neural progenitor cells may be a common cell type of origin.  
An interesting series of cases has been described where parents of three 
children diagnosed with MRTs all worked in the same job site (14).  This leads to 
the intriguing possibility that environmental factors may contribute to 
predisposition to develop mutations or loss of SNF5, as this is an unusually high 
number of cases contained in a shared parental environment.  It has long been 
suspected that parental exposure to toxic substances may lead to the 
development of pediatric brain tumors (15).  Thus, MRTs may be a unique model 
system in which epigenetic effects of toxic agents can be studied. 
A consistent deletion of chromosome 22q11.2 is observed in these 
tumors, with this region containing the SNF5 gene (16).  The vast majority of 
MRTs show either a deletion of SNF5 or an inactivating or truncating mutation, 
resulting in a bi-allelic loss of functional SNF5 (16).  Loss of functional SNF5 can 
also arise from a familial genetic predisposition where one parent contains a 
germline mutation in SNF5 and the child develops a spontaneous mutation in the 
second allele during development (12).  Previous studies have shown that MRTs 
remain genetically stable, with SNF5 loss or mutation as the only consistent 
genetic change (17).  There is a lack of genomic deletions or amplifications, 
chromosomal rearrangements, and DNA repair processes remain intact (17).   
This genomic stability contrasts with loss of other members of the 
SWI/SNF complex.  For example, loss of BRG1 can lead to micronuclei formation 
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and mitotic failure (18).  However, gene expression studies comparing MRTs to 
other pediatric cancers and normal tissues have revealed that despite the genetic 
stability, they display epigenetic instability (17).  There is evidence that the 
SWI/SNF complex can still assemble without the presence of SNF5, but likely 
has abnormal chromatin remodeling activity, which may account for the abnormal 
epigenetic regulation resulting in the observed epigenetic instability (19).  
However, loss of both BRG1 and SNF5 results in a nonfunctional SWI/SNF 
complex, which confirms that there is some residual activity of the complex (4).  
The presence of a partially functional SWI/SNF complex along with genetic 
stability is likely why cells that lose SNF5 are still viable and able to proceed 
through oncogenesis, leading to the development of MRTs.  Such a consistent 
and specific molecular change that occurs in these cancers provides a unique 
tool by which epigenetic studies can be performed in a genomically stable 
environment. 
  When functional SNF5 is introduced into MRT derived cell lines, a G1 
growth arrest and cellular senescence are observed (20).  This indicates that loss 
of SNF5 is critical for the development and sustained growth of these tumors.  
Canonical cell cycle mechanisms appear to be affected by the presence of 
SNF5, including the pRb-E2F pathway (p16INK4A and p21CIP1/WAF1) and p53 (21).  
These genes show significant gene expression changes when SNF5 is 
introduced to MRTs that are thought to contribute to the growth arrest.  This fits 
well with the hypothesis that SWI/SNF is necessary for proper cell cycle control 
and cooperates with the tumor suppressor gene p53 (22). The complex itself can 
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bind to Rb (22), and SNF5 may be important in mediating or regulating the 
subsequent downstream events.  It is important to note that full length functional 
SNF5 is required for growth arrest and the resulting events described above (23).  
This means that mutated or truncated forms of SNF5 that are found in some 
MRT lines, or that are introduced into MRT lines with complete SNF5 deletions, 
are unable to induce a growth arrest (23).   
The full complement of gene promoters that SNF5 directly binds to upon 
introduction into deficient cell lines is not known.  SNF5 has been shown to 
directly bind the p16INK4A and p21CIP1/WAF1 promoters, and SNF5 may modulate 
p21CIP1/WAF1 expression by recruiting p53 to the promoter (24).  However, the 
exact mechanisms of SNF5 mediated growth arrest, such as transcriptional 
regulation or chromatin remodeling at binding sites, remains unclear.  It has been 
observed that introduction of SNF5 leads to repression of Cyclin D1, with direct 
SNF5 binding to its promoter region (25).  The authors observed histone 
deacetylation at the Cyclin D1 promoter, and propose that this leads to reduced 
gene expression and contributes to the G1 growth arrest (25).  However, our 
laboratory has been unable to replicate these results, yet we still observe a 
growth arrest.  This indicates that additional cellular mechanisms may be at play 
upon SNF5 expression. Therefore, it is possible that aberrant expression of 
additional genes and other cellular pathways play a role in the observed growth 
arrest.  A few key cellular pathways are described below that may also be 
important in MRT tumorigenesis:  
 
  
8 
1) Activation of interferon responsive genes after SNF5 introduction 
into MRT lines has been observed (26). This observation may have potentially 
important in vivo roles, as suppression of interferon signaling may be a 
mechanism by which MRTs could evade the immune system.   
2) Mitotic spindle checkpoints were activated and induction of 
apoptosis genes were observed after SNF5 introduction (26).  
3) Loss of SNF5 has also been shown to result in actin cytoskeleton 
disorganization and increased cellular motility, which may play a role in the 
aggressive and invasive nature of this tumor type (27).  
4) The Hedgehog-Gli signaling pathway displays increased activity, 
which may contribute to rapid proliferation of cancerous cells (28). 
Overall, many aberrantly expressed genes and cellular pathways could be 
playing a role in the development of MRTs upon the loss of SNF5 and altered 
SWI/SNF function.  These observations lead to the hypothesis that SNF5 loss 
fuels MRT development through induction of epigenetic instability and aberrant 
gene expression through disruption of SWI/SNF ATP-dependent chromatin 
remodeling in promoter regions.  More specifically, SNF5 reintroduction into 
MRTs will result in chromatin remodeling at target promoters resulting in altered 
gene expression.  In order to test this hypothesis, high throughput screening 
techniques were utilized to find genes whose expression significantly changes 
when functional SNF5 is introduced to MRT cell lines.  Subsequently, the 
proximal promoter regions were then examined using chromatin 
immunoprecipitation to check for evidence of chromatin remodeling activity and 
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epigenetic changes that may have contributed to the observed change in gene 
expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 2: Materials and Methods 
 
 
Cell Culture:  A204.1 (American Type Culture Collection, ATCC) and TTC642 
(Dr. Timothy Triche, Children’s Hospital of Los Angeles) were maintained in 
RPMI 1640 supplemented with 10% fetal bovine serum.  The adenoviral vectors 
Ad/pAdEasyGFPINI-SV+ (Ad-SNF5-GFP) and Ad/pAdEasyGFP (Ad-GFP) have 
been described previously (29).  The adenoviral vector Ad/pAdEasySNF5-HA 
(Ad-SNF-HA) was produced by Dr. Weissman and the UNC Vector Core Facility 
to contain SNF5 with a triple-HA tag at the C terminus.  The Ad-CMV virus was 
obtained from the UNC Vector Core Facility and does not contain a transgene. 
Adenoviral infections were performed at a multiplicity of infection (MOI) to infect 
at least 90% of cells.  The MOI used for A204.1 was 20 and TTC642 was 200.  
Infected cells were collected at the time points indicated in each experiment. 
 
Western Blotting: Protein extractions were performed as described previously 
(20).  30 µg of total proteins were separated on 4-12% SDS-polyacrylamide gels 
by electrophoresis.  Proteins were transferred onto Immobilon-FL PVDF 
membranes (Millipore).  Antibodies used were anti-actin (A2066; Sigma), anti-
CCNH (2927; Cell Signaling), anti-CDK8 (sc-1521; Santa Cruz), anti-CCNG2 (sc-
7266; Santa Cruz), anti-Herc5 (H00051191-A01; Abnova), anti-Herc5 Enzo (gift 
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from Dr. Huibregtse), anti-SNF5 (612110; BD Transduction), anti-Ku (gift from Dr. 
Ramsden), anti-GDF15 (gift from Dr. Eling) and anti-p21CIP1/WAF1 (AB1; 
Calbiochem).  Antibodies were visualized using either IRDye 800CW or IRDye 
680 and with the LI-COR Odyssey Western Blot Detection System or by ECL-
Plus (GE Amersham). 
 
Chromatin Immunoprecipitation: Chromatin immunoprecipitation (ChIP) was 
performed as described previously (30) with the following modifications: protein 
extracts were precleared with 40 µl of 50% protein A/protein G slurry.  
Immunocomplexes were washed once with RIPA buffer, three times with Szak IP 
wash buffer, once with RIPA buffer, then twice with 1x TE.  Immunocomplexes 
were eluted by the addition of 200 µl of 1.5x Talianidis elution buffer and 
incubated at 65°C for 10 minutes.  2 ug of the following antibodies were used for 
immunoprecipitation: Histone H3 (39163, Active Motif), Histone H3 Lysine 4 
trimethylation (H3K4m3, 39159, Active Motif), hSNF5 (Dr. Tony Imbalzano), and 
RNA Polymerase II CTD (MMS-126R, Covance).  Normal rabbit IgG (sc2027, 
Santa Cruz) was used as a negative control.  DNA recovered was quantified by 
an ABI 7900 HT sequence detection system using QT-PCR.  Values were 
normalized to input DNA for each cell line.  The primers used for each promoter 
site are given in Table 1 below. 
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Table 1: QPCR Primers Used for Chromatin Immunoprecipitation Analysis.  Both 
the forward and reverse primers are given for each site in the respective 
promoters examined. 
 
ChIP Primers     
CCNG2 Site Forward Reverse 
-3kb CACACTTGTCAGGAGTCAGGGATT TAATAAGCAGGGAGTGCCCACACA 
-660 AAACTCTCCCGTGGCTGAAA GCGCTTCTCCTAACAGCTAACCTT 
-109 AGAGAGGCTCGAGACGGCAGCTTA ATCCTGCACTTCCTCCACGGACTTTA 
-55 GGAAGTGCAGGATCCCTCCG TTTGTTAAGAGTTTCGACGCCC 
+500 CGCGATGGACAGATAGATGCTCGT AGACTGCCCTTAACCTAGTCGCAA 
+1013 TCAGGTGGGGCAGACCGAGG GTTTCACAAACAGGAAACTGTCCGC 
      
      
HERC5 Site Forward Reverse 
-3kb GTGCACTCATTCTCTAAGCCCACA TGTATCCCAGGTTCTTGCCTTGGT 
-500 CGGCGCACAACGCTTAACAAACTT ACGCATTTCCAGAGGGAGGGATAA 
TSS TTCTCTCCTCTCGCCTCTGGG AGGCGTTCTCTCCTCTCGCCTCT 
+1kb GCGTTTAACTACTGGACGTTTGCG AGCCAGGCAAAGATAAACAGGCA 
   
   
EBox Forward Reverse 
 AAAACGCAGCCACTTGGAGT GCAGAAGTGCGGTTCATCAG 
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RNA extraction and RT-PCR: RNA was extracted using the RNeasy Plus mini kit 
(Qiagen).  cDNA was synthesized using 1 ug RNA primed with random primers 
(Invitrogen).  cDNA was analyzed by RT-PCR using TaqMan (Applied 
Biosystems).  β-actin was used as a reference gene for each reaction.  The ABI 
7900 HT sequence detection system was used and data were analyzed by using 
the 2-ΔΔCt method (31).  The primer/probe sets (Applied Biosystems) used for each 
gene are listed in Table 2 below. 
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Table 2: Primer/Probe sets used for RT-PCR analysis of gene expression.  
Primer/Probe sets were obtained from ABI for determination of relative gene 
expression for the genes identified in this study. 
 
Taqman Gene Expression Assays (ABI)   
Beta-Actin Hs99999903_m1 
CCNG2 Hs00171119_m1 
HERC5 Hs00180943_m1 
p21 Hs00355782_m1 
GDF15 Hs00171132_m1 
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Microarrays: PCR gene expression arrays were performed using a Biosciences 
Human Cell Cycle RT2Profiler PCR Array.  The Ad-RbΔcdk/Ad-SNF5-GFP vector 
system was used with the A204.1 cell line.  Samples were collected 48 hours 
after adenoviral infection, and data was analyzed using the 2-ΔΔCt  method.  Agilent 
4x44k microarrays were used with the Ad-CMV/Ad-SNF5-HA vector system in 
the A204.1 cell line. Samples were collected 9 hours after adenoviral infection, 
and data was analyzed using Partek software. Both array types were performed 
in triplicate. 
 
Cell Cycle Analysis: TTC642 and all clones were infected with an MOI of 200 48 
hours after plating with either Ad-GFP or Ad-SNF5-GFP.  Cells were then 
trypsinized 24 hours later, washed with PBS, and treated with RNAse A and 
propidium iodide for 30 minutes at room temperature.  Cells were stored at 4° C 
until flow cytometry using a DAKO CyAn ADP flow cytometer to measure DNA 
content.  Cell cycle phase was determined using ModFit LT software.  Each 
clone was analyzed in triplicate.
  
 
 
Chapter 3:  RT2Profiler PCR Array   
 
Array Procedure 
 
Since cell cycle control appears to play a large role in SNF5 mediated 
growth arrest, we hypothesized that additional cell cycle related genes would 
show significant expression changes due to the presence of SNF5.  A 
Biosciences Human Cell Cycle RT2Profiler PCR Array was used by a previous 
laboratory member to identify genes whose expression significantly changed 
when SNF5 was introduced into the MRT cell line A204.1.  The genes whose 
expression changed may be binding targets of SNF5 that undergo chromatin 
remodeling and may have biological relevance in mediating the growth arrest.  
This cell line is a soft tissue MRT that contains a TC deletion in exon 5 of the 
SNF5 gene resulting in a loss of protein (32).  This array contained 84 RT-PCR 
reactions with genes primarily involved in cell cycle control or regulation.  
Adenoviral infection of the cell line was performed with Ad-SNF5-GFP or Ad-
RbΔcdk.  RbΔcdk is a constitutively active form of the Retinoblastoma (Rb) tumor 
suppressor gene.  This virus was used to eliminate genes whose expression 
changes due to SNF5 involvement in the induction of Rb pathway or to Rb-
mediated growth arrest, which has been previously characterized (33).  These 
genes are listed in Table 3 below.   
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Table 3: Gene Expression Changes From RT2Profiler Array. Summary of genes 
whose expression significantly changes upon adenoviral infection.  These genes 
are either thought to be part of the Rb mediated growth arrest known to occur in 
Malignant Rhabdoid Tumors upon SNF5 reexpression.  Rb related genes were 
eliminated from further analysis due to the well-characterized nature of the Rb 
mediated arrest in MRTs.  Data are averaged from three independent replicates 
of RT2Profiler Array and are courtesy Dr. Aubri Charboneau and Dr. Bernard 
Weissman. 
 
Table 3: Summary of gene expression common to Ad-RbΔcdk and Ad-SNF5-
GFP infection of A204.1 cells 
Gene Ave. Change (Range) Gene Ave. Change (Range) 
 RbΔcdk SNF5  RbΔcdk SNF5 
Birc5/survivin -4.33  
(-2.03 to -
7.94) 
-1.60 (-1.26 
to -1.90) 
MCM3 -1.64 (-1.39 
to -1.99) 
-2.25 (-
2.01 to -
2.65) 
CCNE1/cyclinE1 -1.63 (-1.39 
to -1.80) 
-1.89 (-1.73 
to -2.06) 
MCM4 -3.21 (-1.90 
to -4.39) 
-2.54 (-
2.22 to -
2.89) 
CDC2 -2.64 
(-2.10 to -
2.92) 
-1.48 (-1.34 
to -1.86) 
MCM5 -2.99 
(-2.12 to -
4.39) 
-1.72 (-
1.54 to -
2.01) 
CDK2 -2.64 
(-2.54 to -
3.11) 
-1.49 (-1.34 
to -1.63) 
RAD51 -3.15 
(-2.15 to -
5.01) 
-1.77 (-
1.11 to -
2.88) 
DDX11 -5.42 
(-4.77 to -
6.19) 
-2.76  
(-1.82 to -
3.73) 
RB1 16.62 
(7.54 to 
25.12) 
1.13 (1.10 
to 1.15) 
MCM2 -2.57 
(-2.20 to -
3.31) 
-1.79 (-1.52 
to -2.14) 
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From this array, six genes were identified where expression increased 
solely due to SNF5 infection (Table 4).  This list included p16INK4A (p16) and 
p21CIP1/WAF1 (p21), which have been previously characterized as having 
increased gene expression after SNF5 reexpression in rhabdoid tumors (24, 33).  
Due to polycomb regulation at the p16 promoter, expression changes were not 
examined any further.  Increased expression of p21 was used as a control for 
infection quality in subsequent experiments. 
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Table 4: Expression Changes Due to SNF5.  Genes whose expression 
significantly changed solely due to the presence of SNF5, from three replicates of 
the RT2Profiler Array. Data are courtesy Dr. Aubri Charboneau and Dr. Bernard 
Weissman. 
 
Table 4: Summary of gene expression changes correlated 
to Ad-SNF5-GFP infection of A204.1 cells 
 
Gene Ave. Change (Range) 
 RbΔcdk SNF5 
CCNG2/cyclinG2 1.39 (1.32 to 1.47) 3.06 (2.27 to 4.06) 
CCNH/cyclinH -0.38 (-1.28 to 1.14) 5.74 (3.63 to 8.25) 
CDK8 -1.18 (-1.35 to -1.00) 2.49 (1.71 to 2.90) 
CDKN1A/p21 0.45 (-1.11 to 1.32) 2.17 (1.82 to 2.54) 
CDKN2A/p16 -1.10 (-1.26 to -1.01) 2.27 (1.50 to 2.99) 
HERC5 0.46 (-1.24 to 1.43) 3.40 (1.74 to 6.21) 
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 This result indicated that the genes identified by the array may have 
biological significance as SNF5 binding targets, and that they may play a role in 
growth arrest.  The other potential targets identified were Cyclin G2 (CCNG2), 
Cyclin H (CCNH), CDK8, and HERC5.  CCNG2, a member of the non-canonical 
Cyclin G family, may function as a negative regulator of the cell cycle and shows 
reduced protein expression in oral cancers (34).  The protein can associate with 
microtubules and overexpression contributes to a p53 mediated G1 growth arrest 
(35).  Expression is high in several terminally differentiated tissues including 
nerve and muscle, further solidifying its role as a negative cell cycle regulator 
(36).  Since the SNF5 mediated growth arrest is p53 dependent in A204.1 (24), 
this further indicates that CCNG2 may play a biologically relevant role in this 
process.  CDK8, a member of the Mediator complex, is recruited to promoters 
undergoing active transcription by RNA Polymerase II (37).  CCNH, which is a 
member of the cdk-activating complex, is involved in cell cycle control (38).  
HERC5 is a Hect3-type E3 ligase involved in conjugation of ISG15 to cellular 
proteins when an innate immune response is activated by interferon (39).  ISG15 
is a ubiquitin like post-translational modification added to proteins when cells are 
undergoing an interferon response (40).  The role of ISG15 modification is 
unknown, but is thought to disrupt protein-protein interactions (40).  Interestingly, 
SNF5 introduction into rhabdoid tumors has been previously shown to activate 
interferon responsive genes, which are thought to contribute to G1 growth arrest 
(26).  HERC5 may induce ISG15 modifications that may lead to the anti-
proliferative effects of interferon stimulation in MRTs. 
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Array Validation 
  
In order to validate the PCR array, we performed individual RT-PCR 
reactions on multiple independent infections.  The Ad-GFP/Ad-SNF5-GFP vector 
system was tested in the A204.1 cell line as well as the TTC642 cell line.  Both of 
these are soft tissue derived MRT cell lines with no functional SNF5 protein 
present.  Like A204.1, TTC642 also contains a mutation in the SNF5 gene, which 
is a C118T transversion that creates a premature stop codon (32).  Time courses 
were performed with three independent infections for both cell lines.  Data for 
both protein and RNA expression was collected for each time course.  A 
representative example of an A204.1 time course mRNA analysis harvested at 
48 hours after infection is given below in Figure 1.  Figure 2 shows a 
representative example of a TTC642 time course.  Examples of protein 
expression by western blot analysis for both cell lines are given in Figure 3. 
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Figure 1:  Data from A204.1 time course.  Samples were collected immediately 
before infection or 48 hours after infection.  mRNA expression for HERC5, 
CCNG2, and p21 are given.  All values are normalized to actin, with relative 
expression shown.  Each gene was examined in triplicate, with error bars 
indicating standard deviation between each replicate.  
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Figure 1A: A204 mRNA Expression 
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Figure 1A Continued: 
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Figure 2: Data from TTC642 time course.  Samples were collected immediately 
before infection or 48 hours after infection.  mRNA expression for HERC5, 
CCNG2, and p21 are given.  All values are normalized to actin, with relative 
expression shown.  Each gene was examined in triplicate, with error bars 
indicating standard deviation between each replicate. 
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Figure 2: TTC642 mRNA Expression 
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Figure 2 Continued: 
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RT-PCR Results 
 
Based on RT-PCR expression data, it appears that CDK8 does not 
increase in TTC642, but does increase in A204.1.  CCNH appears to increase 
with SNF5 expression in both cell lines.  However, preliminary analysis at the 
protein level indicated that these two genes did not show a significant increase.  
Based on the lack of positive controls for the antibodies, these two genes were 
not examined further.  p21 increased significantly in both cell lines with SNF5 
infection, as was expected.  There is a large increase with the Ad-CMV vector in 
the TTC642 cell line, significantly above the other vector controls.  Ad-SNF5-GFP 
still shows a significant increase despite this affect.  HERC5 and CCNG2 only 
increased in the A204.1 cell line.  HERC5 alone is increased in TTC642, yet it is 
not significant when compared to the controls. 
 
Protein Expression Results 
 
p21 showed a consistent increase in protein expression in both cell lines.  
The large p21 expression increase seen with Ad-CMV in TTC642 is not observed 
at the protein level.  Two HERC5 antibodies were used, one commercially 
available and another received from a collaborator (Jon Huibregtse, UT Austin).  
The latter is labeled as HERC5 Enzo, as it was developed in conjunction with 
Enzo Biosciences and is believed to soon be commercially available.  While 
A204.1 does not show any increase in HERC5 protein, TTC642 does show a 
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significant increase when examined by the commercially available antibody.  This 
may be explained by the magnitude differences in HERC5 expression between 
the cell lines.  A204 only increases four fold over the uninfected mass population, 
while TTC642 shows an increase of over 30 fold.  CCNG2 did not show a protein 
increase in either cell line, even though the message increased.  Further analysis 
is needed to determine why the protein levels do not follow message levels.  As 
Cyclin G2 is involved in cell cycle regulation, its expression may be tightly 
regulated.  Both actin and ku were used as loading controls, and SNF5 was 
probed for to verify successful infection with the Ad-SNF5-GFP virus.  Ku is a 
nuclear protein, so it may give a more accurate representation of loading for 
nuclear proteins than actin. 
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Figure 3: Protein expression from A204.1 and TTC642 time courses.  (A) Protein 
expression from A204.1 (B) Protein expression from TTC642. Proteins examined 
include actin, ku, CCNG2, HERC5 (abcam and Enzo), p21, SNF5. 
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Figure 3A: A204.1 Protein Expression  
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Figure 3B: TTC642 Protein Expression 
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Cell Cycle Analysis 
  
In order to determine if CCNG2 plays a biologically relevant role in SNF5 
mediated growth arrest, CCNG2 knockdowns were generated using stable cell 
lines containing siRNA against CCNG2.  Three clones, along with a non-specific 
control, were generated in the TTC642 cell line by Dr. Yasumichi Kuwahara.  The 
non-specific control used was PLKO, which is thought not to target any known 
sequence in the human genome.  Generating knockdowns was not possible in 
A204.1, as attempts to do so resulted in complete cell death.  Analysis of CCNG2 
protein and mRNA expression for all clones are given in Figure 4A and B, 
respectively.  As seen in lane 5 of Figure 4A, only siCCNG2 clone 3 showed a 
decrease in expression of CCNG2 at the protein level.  However, the message is 
decreased only for clones one and two, when compared to PLKO and the mass 
population (Figure 4B).  The difficulty in generating a complete knockdown may 
be an indication that the presence of CCNG2 is necessary for survival of MRT 
cell lines.   
Two clones, along with the mass population and control, were analyzed 
for cell cycle analysis 24 hours after Ad-SNF5-GFP infection.  The population of 
cells in G1/G0, S, and G2/M phase were identified using propidium iodide 
staining to determine DNA content by flow cytometry and analysis using ModFit 
LT software.  The average of three independent infections in each of the clones 
are shown below in Figure 4C.  For each experiment, uninfected cell, Ad-GFP, 
and Ad-SNF5-GFP were examined simultaneously to check for differences in 
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growth arrest.  It appears that there is a cell cycle defect in clone 3, where there 
is not a large change in S phase population between uninfected and Ad-SNF5-
GFP infected.  This may indicate that CCNG2 does indeed play a role in SNF5 
mediated growth arrest.  Based on these experiments, it is unclear whether the 
growth arrest is simply delayed, or there is a true defect in the knockdown cells.  
Further experimentation is necessary to determine the exact nature and 
biological relevance of the differences in cell cycle populations among the 
CCNG2 knock down clones. 
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Figure 4: Analysis of CCNG2 knock down cell lines. (A) Protein expression of 
CCNG2 in stable knock down cell lines in the TTC642 cell line.  Actin is used as 
a loading control.  (B) Relative mRNA expression in each clone compared to the 
mass population of TTC642 cells. (C) Cell cycle analysis depicting populations in 
the G1 or S phase of the cell cycle.  Error bars represent standard deviation 
between three independent experiments. 
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Figure 4A: siCCNG2 Western Blot Analysis 
 
 
 
 
 
Figure 4B: siCCNG2 mRNA Analysis 
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Figure 4C: siCCNG2 Cell Cycle Analysis 
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Chapter 4:Chromatin Immunoprecipitation 
 
 
 CCNG2 and HERC5 were chosen as the two strongest candidates 
discovered in the PCR array described in Section 1.  In order to confirm these 
genes as true binding sites of SNF5, chromatin immunoprecipitation (ChIP) was 
performed across the promoter region of the gene of interest.  This technique is 
used to indicate that SNF5 is directly binding to the promoter by precipitating 
short DNA fragments with an anti-SNF5 antibody.  Briefly, this technique involves 
cross-linking proteins to DNA. The DNA is then sonicated into short fragments 
and antibodies against the proteins are used to immunoprecipitate fragments of 
DNA to which they are bound. This was done in both Ad-GFP and Ad-SNF5-GFP 
infected samples to determine the level of background for each antibody used.  
ChIP has been used by our lab in the past to show SNF5 binding to the p16 and 
p21 promoters (20, 24).  In addition to SNF5 binding, other epigenetic and 
transcriptional markers can be assayed by ChIP to indicate chromatin remodeling 
or the presence of the SWI/SNF complex at the promoter region.  These marks 
can be used to confirm the genes as true SNF5 binding targets and can indicate 
chromatin-remodeling events that may contribute to the altered gene expression 
identified in the array.  Primers spanning the promoter region, as well as a 
nonspecific upstream region, were designd to generate 60-75 base pair products.  
Six primers were designed in the promoter region of CCNG2, with three 
 
  
39 
upstream of the transcription start site, one on the transcription start site and two 
downstream sites.  The sequences of the primers and genomic locations are 
given in Table 1.  The +1013 site was designed based off work performed by 
Stossi et al (41).  For HERC5, four sites were chosen using a similar method, 
also given in Table 1.  DNA recovered by ChIP was used as input for qPCR, 
where the level of signal was used to indicate amount of DNA pulled down by the 
immunoprecipitation.  The data were then normalized to total genomic DNA and 
analyzed by the percent recovery technique.  This technique compares the 
amount of recovered DNA to input DNA, giving an idea of the amount of 
chromatin recovered by a particular immunoprecipitation (42).  Our lab has 
traditionally used the E-BOX region as a negative control for this vector system, 
as there is no evidence for SWI/SNF binding to this region (24).  ChIP analysis of 
the EBOX promoter is given in Figure 7 
ChIP analysis for the CCNG2 promoter region is given in Figure 5.  The 
background for both infections is similar, as seen in the normal Rabbit IgG 
immunoprecipitation.  SNF5 shows a clear binding across the promoter region in 
the Ad-SNF5-GFP infected sample, at significantly higher recovery than Ad-GFP 
infected cells.  While not statistically significant, there appears to be a trend of 
decreased Histone H3 occupancy and increased H3K4 trimethylation, which is a 
marker of active transcription.  There are also no changes in RNA Polymerase II 
binding across the promoter region.  The meaning of this is unclear, but it may be 
due to a basal level of CCNG2 transcription.  Also, some form of the SWI/SNF 
complex may already be present at the promoter region, but its remodeling 
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activity may be inadequate to generate a high level of transcription without 
functional SNF5.  Restoration of proper remodeling activity then may not show an 
increase in levels of the polymerase. 
 ChIP analysis of the HERC5 promoter region is shown in Figure 6.  There 
is a clear binding of SNF5 to the promoter region, though it is significantly less 
than SNF5 binding to the CCNG2 promoter.  There is a similar trend of 
decreased Histone H3 occupancy in the promoter.  An increase in H3K4m3 at 
the transcription start site is observed, but not at other sites within the promoter 
region.  There is a large drop in the amount of RNA Polymerase II across the 
entire promoter region. 
 There is not a significant amount of SNF5 binding to the EBOX promoter 
(Figure 7).  When compared to CCNG2 and HERC5, both the SNF5 and RNA 
polymerase II levels are near IgG background.  This indicates that there are 
distinct differences between expressed and unexpressed genes that can be seen 
by ChIP analysis.   
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Figure 5: CCNG2 ChIP Analysis.  ChIP analysis of the CCNG2 promoter region 
in A204.1 cells 24 hours after SNF5 introduction.  Ad-GFP infections are shown 
in blue, Ad-SNF5-GFP infections are shown in red.  Error bars indicate standard 
deviation between replicates.  Two replicates for each promoter site were 
completed.  Antibodies used include RNA Polymerase II CTD, total Histone H3, 
Histone H3 Lysine 4 trimethylation, SNF5 (Imbalzano), and normal rabbit IgG.  
Data are normalized to input DNA or Histone H3 (Histone H3K4m3 only). 
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Figure 5: CCNG2 ChIP Analysis 
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Figure 5 Continued: 
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Figure 5 Continued: 
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Figure 6: HERC5 ChIP Analysis.  ChIP analysis of the HERC5 promoter region 
in A204.1 cells 24 hours after SNF5 introduction.  Ad-GFP infections are shown 
in blue, Ad-SNF5-GFP infections are shown in red.  Error bars indicate standard 
deviation between replicates.  Two replicates for each promoter site were 
completed.  Antibodies used include RNA Polymerase II CTD, total Histone H3, 
Histone H3 Lysine 4 trimethylation, SNF5 (Imbalzano), SNF5 (Bethyl), and 
normal rabbit IgG. 
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Figure 6: HERC5 ChIP Analysis 
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Figure 6 Continued: 
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Figure 6 Continued: 
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Figure 7: ChIP analysis of the EBOX promoter region.  Antibodies are the same 
as described previously. Ad-GFP infections are shown in blue, Ad-SNF5-GFP 
infections are shown in red.  Error bars indicate standard deviation between two 
replicates. 
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Chapter 5: Gene Expression Array 
 
 
 The SWI/SNF complex is ubiquitously expressed in human tissues, and it 
is present throughout development.  Due to this fact, many genes involved in 
diverse cellular processes can undergo SWI/SNF mediated chromatin 
remodeling.  The previous array was used to examine a specific subset of genes 
for SNF5 binding that are involved in a single cellular pathway.  This is a narrow 
approach to identifying novel binding sites and genes that are involved in SNF5 
mediated growth arrest in MRTs.  However, it provided valuable insight into the 
possibility that high-throughput techniques could be utilized to examine SNF5 
binding sites.  To get an idea of different pathways that may be changing due to 
the presence of SNF5, whole genome gene expression microarrays were 
chosen. 
 For this procedure, a different vector system was utilized in order to 
reduce possible confounding factors, such as the presence of GFP.  This system 
utilized an empty adenoviral vector, Ad-CMV, that does not contain any 
transgene that could be expressed.  This made an ideal control to account for 
any nonspecific gene expression changes due to adenoviral infection itself.  
SNF5 was introduced using Ad-SNF5-HA, which contains a triple-HA tag on the 
C-terminus of the SNF5 gene.  This novel vector system eliminates GFP and 
provides the HA tag by which SNF5 expression can be determined.  The ability to 
IP with the HA tag offers an improvement in additional methods of determining 
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SNF5 expression or binding in a variety of applications.  In order to detect the 
immediate binding targets of SNF5 and not downstream or subsequent binding 
targets, western blotting was used to determine the earliest time point in which 
SNF5 could be detected.  Ideally, this will give the immediate binding sites of 
SNF5 and reduce the number of false positives.  The HA antibody was used to 
assess SNF5 expression, as it is more sensitive than SNF5 antibodies.  SNF5 
expression is first visible at 9 hours after infection (Figure 8), so this time point 
was chosen for microarray analysis. 
 
  
52 
 
Figure 8: Ad-SNF5-HA Protein Expression.  Western blot showing A204.1 at 
various time points (in hours) after Ad-SNF-HA infection.  Anti-HA antibody 
indicates 9 hours as the earliest time point for SFN5 expression. 
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 A204.1 cells were infected and collected 9 hours after infection in the 
same manner as described in the previous chapters.  RNA was submitted to the 
UNC Genomics Core Facility for hybridization to Agilent Human 4x44k Whole 
Genome arrays.  This array contains transcript sequences from over 41,000 
human genes.  Agilent array technology allows for up to four replicates per run, 
yielding high confidence in the data obtained.  Both Ad-SNF5-HA infected 
samples and Ad-CMV infected samples were hybridized in triplicate.  This was 
performed by labeling the sample with Cy5 and the reference with Cy3.  The 
reference used in this case was RNA obtained from the mass population of 
A204.1 cells.  Data was processed using Agilent Feature Extraction software, 
and dye normalization was automatically performed by adjusting for intensity-
dependent dye variation by Lowess Normalization (43).  Further analysis was 
performed in Partek software.  Genes whose expression changes in both Ad-
CMV infected and Ad-SNF5-HA infected samples were eliminated from analysis, 
due to the likelihood that they are altered due to adenoviral infection.  Genes 
were clustered together in an unsupervised approach for visualization and to 
determine patterns of expression, a technique that has previously been used by 
our laboratory (44).  
 Principal Components Analysis (PCA) was used to determine the 
variability between replicates.  As seen in Figure 9, the replicates were similar in 
their overall gene expression patterns, indicating a low amount of error between 
each hybridization reaction.  The only gene that emerged as statistically 
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significant at this time point was GDF15.  The expression of the potential binding 
targets identified by the original PCR array were also examined.  While the 
expression of p21 increases on two different probes on the array, these and all 
other changes were not statistically significant.  The full analysis is presented in 
Table 5. 
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Figure 9:  Principle Components Analysis.  PCA analysis of Agilent 4x44K 
Human Gene Expression arrays performed in triplicate for the A204.1 cell line 9 
hours after SNF5 infection using the Ad-SNF5-HA vector.  The data indicate 
there is high precision among the replicates.  Each microarray is shown in a ball, 
and each vector is grouped together with a circular net.  Ad-CMV microarrays are 
shown in red on the right, and Ad-SNF5-HA arrays are shown in blue on the left. 
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Table 5: Gene Expression Array Results.  Results from the combination of three 
replicates of Agilent 4x44K Human Gene Expression arrays.  (A) Examination of 
potential target genes identified in the RT2Profiler PCR array.  Comparison of Ad-
SNF5-HA cells to uninfected, mass population A204.1 cells.  While p21 
increases, no changes are statistically significant. (B) Comparison of gene 
expression in Ad-SNF5-HA vs. Ad-CMV at the 9-hour time point.  Only GDF15 
emerged as a statistically significant target. * = p=5.65e-6 
 
(A). Ad-SNF-HA vs. Mass 
Population   
p21 1.33026 
p21 1.52815 
CCNG2 1.17115 
CCNG2 -1.00784 
CCNH 1.04945 
CDK8 -1.11492 
HERC5 -1.12318 
    
(B). Ad-SNF-HA vs. Ad-CMV   
GDF15 2.07164* 
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The fact that none of the genes identified by the RT2Profiler PCR array 
were identified as significant in the Agilent 4x44K array is not surprising.  The 
RNA collected for the array was harvested 9 hours after infection, while the RNA 
used for the RT2Profiler array was harvested 48 hours after infection.  This time 
point may be too early to detect all of the changes that are occurring in gene 
expression, as there may still be low levels of SNF5 present in the cells. 
 GDF15 (Growth Differentiation Factor 15, NAG1, MIC-1) is a potential 
tumor suppressor gene that is regulated by histone acetylation (45).  There is 
some evidence that this gene is down regulated in some brain tumors (45).  As 
MRTs can arise in the brain, this is a potentially interesting and biologically 
relevant gene to understanding SNF5 function and MRT development.  The 
protein is a member of the Tumor Growth Factor-β family, and is a downstream 
target of p53 (46).  To assess GDF15 expression, RT-PCR was used with both 
Ad-SNF5-GFP and Ad-SNF5-HA 48 hours after infection.  Although GDF15 was 
identified at the 9 hour time point, the 48 hour time point was chosen for 
consistency with other experiments.  The expression of GDF15 in both A204.1 
and TTC642 is shown in Figure 10.  The largest mRNA increase appears to 
occur with the Ad-SNF5-GFP vector in both cell lines.  However, it does 
significantly increase with the Ad-SNF5-HA vector in both cell lines.  Western 
blotting shows an increase in protein expression in both cell lines, consistent with 
the mRNA expression data (Figure 11).  Further analysis of GDF15, including 
positive controls to more confidently confirm protein expression, is needed. 
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Figure 10: Analysis of GDF15 Expression by RT-PCR.  (A) Expression in the 
A204.1 cell line.  (B) Expression in the TTC642 cell line.  Both cell lines were 
examined 48 hours after simultaneous infection with vector systems.  Error bars 
indicate standard deviation between three replicates of one infection for each cell 
line. 
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Figure 10A: 
 
 
Figure 10B: 
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Figure 11:  GDF15 Protein Expression in A204.1 and TTC642 time courses.  
A204.1 is given on top, followed by TTC642 on the bottom.  Increases in protein 
level can be seen in both Ad-SNF5-GFP and Ad-SNF5-HA lanes at 48 hours 
after infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 6: Discussion and Conclusions 
 
Induction of gene expression, via restoration of functional SNF5 in MRTs, 
may be due to restoration of proper SWI/SNF maintenance of nucleosome 
positioning and epigenetic marking in their promoter regions.  Based on current 
knowledge, both CCNG2 and HERC5 can contribute to processes that induce a 
growth arrest, and GDF15 is dependent on histone acetylation.  This property of 
GDF15 fits well with our hypothesis.  The growth arrest capabilities of CCNG2 
and HERC5 also make sense as SNF5 introduction leads to growth arrest.  ChIP 
analysis of both regions reveals SNF5 binding and possible epigenetic 
alterations.  However, the level of SNF5 binding at the HERC5 promoter region is 
less than the CCNG2 region, though significantly higher than the EBOX 
promoter.  As the EBOX promoter is a negative binding site, this indicates that 
SNF5 is being recruited to the HERC5 promoter.  The lack of protein increase to 
match the mRNA increase seen in A204.1 is concerning.  There is no visible 
increase with the Enzo antibody, and the Abcam antibody shows a slight but 
likely not significant increase.  However, HERC5 can be post-translationally 
modified, which may maintain a consistent protein level even in the presence of 
drastically increased message.  Free ISG15, the substrate of HERC5, should 
decrease as HERC5 expression and conjugation activity increases (39).  An 
expression increase of 8 fold was observed in the vector system used by Dastuer 
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et al, resulting in significant HERC5 conjugation (39).  This level of expression 
was achieved in TTC642, therefore it is likely that HERC5 functional activity may 
be increased even without observing a protein increase.  Since the HERC5 
expression in TTC642 also increased with vector controls, ChIP analysis of the 
promoter region in this cell line may give an indication if this gene is a SNF5 
binding target in both cell lines.  Examination of ISG15 levels as well as other 
proteins involved in the HERC5 mediated interferon response pathway is 
warranted to further validate or refute this gene as a SNF5 target.  Based on the 
current data, we cannot rule out that HERC5 may be a novel binding target.   
The protein expression of CCNG2 does not increase in either cell line, and 
mRNA expression only increases in the A204.1 cell line.  This may be a result of 
tight regulation due to its role in cell cycle control.  The fact that attempts to 
knock down CCNG2 expression in A204.1 failed indicates that some level of 
expression may be essential for survival.  Cell cycle analysis of knockdowns in 
TTC642 indicated the possibility of a delayed or reduced growth arrest.  These 
two results taken together may indicate that CCNG2 plays a biologically 
significant role in SNF5 mediated growth arrest.  The ChIP results showing 
strong SNF5 binding, and RT-PCR showing a RNA increase lead us to believe 
that CCNG2 is indeed a binding target of SNF5 despite the lack of protein 
increase.  More extensive ChIP analysis of the promoter region including 
additional epigenetic marks or SWI/SNF complex members may shed light on 
other changes that are occurring to alter gene expression.  Examination of 
H3K27 trimethylation and polycomb proteins could provide valuable information.  
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Epigenetic antagonism between the SWI/SNF complex and the polycomb 
complexes has been observed, with increased expression of some polycomb 
proteins in SNF5 deficient models such as MRTs (47).  It is also unclear why the 
amount of RNA Polymerase II decreases at both the HERC5 and CCNG2 
promoters after SNF5 expression.  The immunoprecipitation performed examined 
total RNA Polymerase II.  Examination of phosphorylation status may indicate if 
there is a change in the amount of active elongating polymerase or inactive 
polymerase.  There may be less overall polymerase, but more of the polymerase 
could be actively transcribing the gene.  It is known that RNA Polymerase II can 
pause at the +1 nucleosome position, and nucleosome remodeling can alter 
pausing and gene transcription (48).  This may explain why the levels in the 
promoter appear to decrease while mRNA expression increases.  The other 
genes identified in the RT2Profiler Array, CDK8 and CCNH, do not appear to be 
novel SNF5 targets.    
The PCA analysis shows good reproducibility between the hybridizations, 
yielding high confidence in the data (Figure 9).  GDF15 increased with both 
vector systems in both cell lines at the message level.  This indicates that the 
early expression change, identified at the 9 hour time point, remains in place at 
the 48 hour time point.  Accordingly, the change is likely due to the presence of 
SNF5 and not a nonspecific response due to adenoviral infection.  The protein 
expression increases significantly for both SNF5 vector systems in both cell lines.  
ChIP analysis of the GDF15 promoter region will reveal any SNF5 binding or 
epigenetic alterations.  Analysis of histone modifications, such as acetylation, will 
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provide valuable insight into the mechanism of expression changes.  Restoration 
of functional SWI/SNF may result in increased histone acetylation, as this is a 
mechanism of GDF15 regulation (45).  Introduction of GDF15 into deficient 
cancer cell lines can reduce cell motility and invasiveness (46).  If MRTs express 
comparatively low levels of GDF15 compared to normal cells, discovery of this 
protein may have revealed a key factor behind the aggressive nature of this 
cancer.  The p53 regulation of this gene also fits nicely with the p53 dependent 
cell cycle arrest observed in some MRT lines (24, 46).  Others have observed 
that GDF15 can act as a mediator of the p53/p21 pathway when a growth arrest 
is triggered (49).  Such observations tie in with the original motivation behind this 
work to identify genes that may be contributing to the SNF5 mediated G1 growth 
arrest.  Use of the genome wide Agilent 4x44k array at a later time point may 
reveal additional genes that may contribute to cell cycle arrest.  The use of the 
array at 9 hours indicated that this is a useful high throughput technique to 
identify novel binding targets of SNF5 that may not be cell cycle related. 
Taken together, the inconsistent mRNA and protein expression results 
indicate that there is variability among MRT cell lines.  As the cell type of origin is 
unknown, this may be an indication that different cell types are able to undergo 
transformation into MRTs.  This could result in an inherent difference in basal 
gene expression differences before and after transformation.  This may be why 
the magnitude of changes in expression after introduction of functional SNF5 into 
A204.1 and TTC642 could differ.  Overall, it appears that CCNG2, HERC5, and 
GDF15 may be genes whose expression changes when SNF5 is introduced into 
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MRTs.  They may play a role in the observed growth arrest; however, further 
characterization is warranted to solidify this hypothesis.  Discovery of these 
genes as well as their connection to SNF5 may provide valuable information on 
how MRTs develop. These insights have the potential to provide novel 
treatments for MRTs that may be safer and more effective that the currently 
available options.  Both clinicians and basic science researchers will gain 
valuable information into the molecular mechanisms behind this deadly pediatric 
cancer, that may ultimately improve the poor prognosis for this rare disease. 
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